Research to be published in a leading scientific journal reveals how Clever-1 is important in the process of humoral immunity.
Clever-1 is a cell surface receptor shown to control a certain form of immunity.
Data carried by Frontiers in Immunology suggest that disrupting the function of Clever-1 probably does not lead to the suppression of antibody production.
Rather it could improve humoral immune responses against tumour antigens and during vaccinations.
Faron Pharma (LON:FARN) is developing a fully human anti-Clever-1 antibody called Clevegen.
It said the efficacy of anti-Clever-1 antibodies in experimental models supported the development of its potential cancer immunotherapy, which is due to enter the clinic later this year.
Faron chief executive, Dr Markku Jalkanen, said: "This is a fascinating finding and builds up further evidence for the importance to control Clever-1 function in conditions where active immune suppression can cause disease or worsen disease development.
“It provides further scientific rationale for our Vaccination Response Enhancement Technology programme, which is currently under early investigation with Clevegen."